Emerging Therapies in the Treatment of Central Precocious Puberty: A Review for Specialty Pharmacists

Emerging Therapies in the Treatment of Central Precocious Puberty: A Review for Specialty Pharmacists

Faculty
Dennis M. Styne, MD
Yocha Dehe Chair of Pediatric Endocrinology
Professor of Pediatrics
University of California
Sacramento, California

Medical Writing Support
Lori Uildriks, PharmD, BCPS, BCGP
Clinical Pharmacist/Clinical Instructor
Department of Pharmacy Practice
University of Illinois at Chicago College of Pharmacy
Chicago, Illinois
 

---

Activity Overview
The onset of puberty is typically between ages 8 and 13 years for females and 9 and 14 years for males. Classic manifestations of puberty include development of breasts and menarche for girls and voice changes and testicular enlargement in boys, among other signs. However, an estimated 1 in 1000 to 1 in 10,000 children may experience central precocious puberty (CPP), or the premature development of these and other secondary sex characteristics. Long-acting GnRH analogs are the mainstay of treatment for CPP and stabilize the progression of puberty through continuous stimulation of pituitary gonadotropins. Pharmacists should be knowledgeable about the signs and symptoms of this rare condition and associated therapeutic regimens to best counsel patients and their families about potential short-term and long-term effects of treatment. GnRH analogs are unique medications with special handling, storage, and distribution requirements, making the specialty pharmacist instrumental in facilitating their access and proper utilization. From recommending screening and treatment initiation for CPP to assisting with administration and access to these medications, specialty pharmacists can be involved in decreasing clinical burden, improving quality of life, and optimizing outcomes for patients with CPP. 

Target audience: Specialty pharmacists
Activity type: Application
Release date: February 26, 2021
Expiration date: June 15, 2022
Estimated time to complete activity: 2.0 hours
Fee: Free

Educational Objectives
At the completion of this activity, the participant will be able to:

• Identify the epidemiology, etiology, clinical presentation, diagnosis, and clinical burden of central precocious puberty (CPP)
• Examine the treatment landscape of CPP and compare pharmacologic therapies used for this condition
• Explain the role of the specialty pharmacist in addressing unmet needs for patients with CPP to optimize clinical and economic outcomes

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.2 CEU) under the ACPE universal activity number: 0290-0000-21-006-H01-P. The activity is available for CE credit through June 15, 2022.


Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
 

---

Disclosures

Dennis M. Styne, MD, has the following relevant financial relationships with commercial interests to disclose:
Stock/Shareholder: Bristol Myers Squibb, Teva, Organon & Co.

Lori Uildriks, PharmD, BCPS, BCGP, has no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™
Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Kimberly Simpson, PharmD; Ann Marciano; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose.

Anonymous peer reviewers were used as part of the content validation and conflict resolution and have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms